Smith, Moore & Co. Mirati Therapeutics, Inc. Transaction History

Smith, Moore & Co.

  • $961 Million
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$39.16 - $88.71 $117,479 - $266,130
3,000 New
3,000 $201,000
Q1 2022

May 12, 2022
SELL
$75.82 - $150.97 $151,640 - $301,940
-2,000 Closed
0 $0
Q4 2021

Feb 08, 2022
BUY
$132.01 - $190.29 $66,005 - $95,145
500 Added 33.33%
2,000 $293,000
Q3 2021

Nov 12, 2021
BUY
$132.13 - $177.45 $198,195 - $266,175
1,500 New
1,500 $265,000

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Smith, Moore & Co. Portfolio

Follow Smith, Moore & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smith, Moore & Co., based on Form 13F filings with the SEC.

News

Stay updated on Smith, Moore & Co. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email